UAE First to Approve New Breast Cancer Oral Therapy

Women with advanced breast cancer who've run out of treatment options just got a powerful new lifeline, and it's coming from the UAE.

The Emirates Drug Establishment approved Etcamah this week, making the UAE the first country in the world to greenlight this innovative oral therapy. The treatment targets patients with advanced or metastatic breast cancer who've developed resistance to hormone therapy, a common and frustrating setback in cancer care.

Unlike traditional treatments, Etcamah works by blocking and degrading estrogen receptors directly in cancer cells. This dual action slows tumor growth and prevents the cancer from spreading further through the body.

The approval came after the drug showed strong results in a Phase III clinical trial called SERENA-6. Patients who had developed mutations while receiving standard hormone therapy saw significant improvements in progression-free survival, meaning they lived longer without their cancer getting worse.

Dr. Fatima Al Kaabi, Director General of the Emirates Drug Establishment, says the approval strengthens the UAE's healthcare sector. "Through advanced assessment tools that balance accelerated access with the highest standards of safety and quality, we will continue to reinforce the UAE's position as a trusted reference point for pharmaceutical innovation," she said.

The Ripple Effect

This approval extends far beyond the UAE's borders. As the first country to approve Etcamah, the UAE is paving the way for faster regulatory reviews in other nations, potentially helping breast cancer patients worldwide access this treatment sooner.

Breast cancer remains one of the most common cancers among women globally. Every new treatment option means more patients can find something that works for their specific type of cancer, especially when first-line therapies fail.

The Emirates Drug Establishment emphasized that early detection still matters most. Regular screenings, sticking to prescribed treatment plans, and maintaining follow-up appointments with doctors all play vital roles in improving outcomes and quality of life.

For women facing advanced breast cancer with limited options, this new oral therapy represents exactly what medicine should deliver: hope backed by science.